Saad S Kenderian

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8506123/saad-s-kenderian-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112 papers	2,418 citations	22 h-index	48 g-index
119 ext. papers	3,343 ext. citations	5 avg, IF	5.24 L-index

#	Paper	IF	Citations
112	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. *Blood Cancer Journal*, **2022**, 12, 18	7	1
111	Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.. *Blood*, **2022**,	2.2	4
110	Challenges of CAR T-cell Therapy in CLL: Lessons Learned.. *Experimental Hematology*, **2022**,	3.1	2
109	Combination Therapeutics with CAR-T Cell Therapy. *Cancer Drug Discovery and Development*, **2022**, 69-90	0.3	
108	CAR T‐cell therapy and the tumor microenvironment: Current challenges and opportunities.. *Molecular Therapy - Oncolytics*, **2022**, 25, 69-77	6.4	4
107	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. *Blood Cancer Journal*, **2022**, 12, 62	7	0
106	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. *Blood*, **2021**, 138, 901-901	2.2	0
105	A Phase 2/3 Randomized, Placebo-Controlled, Open-Label, Multi-Center Trial of Lenzilumab to Improve the Safety and Efficacy of CAR-T Cell Therapy in Adults with Relapsed or Refractory Large B-Cell Lymphoma (The SHIELD Study). *Blood*, **2021**, 138, 1758-1758	2.2	
104	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory). *Blood*, **2021**, 138, 1560-1560	2.2	
103	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. *Blood*, **2021**, 138, 568-568	2.2	0
102	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. *Hematological Oncology*, **2021**,	1.3	0
101	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. *American Journal of Hematology*, **2021**, 97, 90	7.1	4
100	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. *Leukemia and Lymphoma*, **2021**, 62, 2052-2063	1.9	3
99	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. *Blood Cancer Journal*, **2021**, 11, 47	7	1
98	CART cell imaging: Paving the way for success in CART cell therapy. *Molecular Therapy - Oncolytics*, **2021**, 20, 625-633	6.4	4
97	In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. *Mayo Clinic Proceedings*, **2021**, 96, 817-818	6.4	1
96	Leukemic extracellular vesicles induce chimeric antigen receptor T‐cell dysfunction in chronic lymphocytic leukemia. *Molecular Therapy*, **2021**, 29, 1529-1540	11.7	12

95	The prognostic significance of del6q23 in chronic lymphocytic leukemia. *American Journal of Hematology*, **2021**, 96, E203-E206	7.1	1
94	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. *Blood Cancer Journal*, **2021**, 11, 86	7	4
93	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. *Annals of Hematology*, **2021**, 100, 143-155	3	7
92	CRISPR Takes the Front Seat in CART-Cell Development. *BioDrugs*, **2021**, 35, 113-124	7.9	6
91	Upregulation of AXL and Ecatenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. *Blood Cancer Journal*, **2021**, 11, 37	7	
90	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. *Cancer Immunology Research*, **2021**, 9, 1035-1046	12.5	2
89	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. *Blood Cancer Journal*, **2021**, 11, 140	7	0
88	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. *Transplantation and Cellular Therapy*, **2021**, 27, 738-746		2
87	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. *Cancer Medicine*, **2020**, 9, 3390-3399	4.8	19
86	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a Sgraft versus hostSlike syndrome and poor outcomes. *Bone Marrow Transplantation*, **2020**, 55, 1879-1881	4.4	1
85	Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nature Biotechnology*, **2020**, 38, 947-953	44.5	290
84	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. *American Journal of Hematology*, **2020**, 95, 1170	7.1	1
83	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. *Bone Marrow Transplantation*, **2020**, 55, 1525-1532	4.4	11
82	Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy. *Blood*, **2020**, 136, 6-7	2.2	0
81	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. *Blood*, **2020**, 136, 26-27	2.2	
80	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. *Blood*, **2020**, 136, 10-12	2.2	
79	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. *Blood*, **2020**, 136, 28-29	2.2	
78	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. *Blood*, **2020**, 136, 30-31	2.2	1

77	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. *Blood*, **2020**, 136, 3-4	2.2	
76	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 12-13	2.2	
75	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 1-1	2.2	
74	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. *Blood*, **2020**, 136, 30-31	2.2	1
73	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 16-17	2.2	1
72	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 49-50	2.2	1
71	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 50-51	2.2	
70	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. *Blood*, **2020**, 136, 39-40	2.2	1
69	ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). *Blood*, **2020**, 136, 6-7	2.2	4
68	CART Cell Toxicities: New Insight into Mechanisms and Management. *Clinical Hematology International*, **2020**, 2, 149-155	1.8	10
67	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. *Haematologica*, **2020**, 105, 2675-2678	6.6	11
66	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. *Leukemia and Lymphoma*, **2020**, 61, 2383-2388	1.9	11
65	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. *Current Opinion in Hematology*, **2020**, 27, 41-48	3.3	4
64	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. *American Journal of Hematology*, **2020**, 95, E57-E60	7.1	5
63	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. *Oncologist*, **2020**, 25, 974-980	5.7	5
62	Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. *Lancet Haematology,the*, **2020**, 7, e816-e826	14.6	34
61	A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. *Neurologic Clinics*, **2020**, 38, 953-963	4.5	7
60	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. *Clinical Cancer Research*, **2020**, 26, 5759-5771	12.9	2

59	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. *Mayo Clinic Proceedings*, **2020**, 95, 2382-2394	6.4	54
58	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. *Frontiers in Immunology*, **2020**, 11, 1973	8.4	48
57	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. *Haematologica*, **2020**, 105, 765-773	6.6	31
56	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2020**, 4, 203-210	3.1	3
55	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). *Bone Marrow Transplantation*, **2019**, 54, 1868-1880	4.4	55
54	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. *Leukemia and Lymphoma*, **2019**, 60, 2712-2719	1.9	28
53	Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. *Journal of Visualized Experiments*, **2019**,	1.6	18
52	Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. *Immunotherapy*, **2019**, 11, 851-857	3.8	34
51	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. *Leukemia*, **2019**, 33, 2767-2778	10.7	34
50	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 865-865	2.2	9
49	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. *Blood*, **2019**, 134, 53-53	2.2	1
48	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). *Blood*, **2019**, 134, 4306-4306	2.2	3
47	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 679-679	2.2	1
46	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. *Blood*, **2019**, 134, 3050-3050	2.2	2
45	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. *Blood*, **2019**, 134, 4106-4106	2.2	4
44	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. *Blood*, **2019**, 134, 3868-3868	2.2	5
43	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. *Blood*, **2019**, 134, 5352-5352	2.2	
42	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 4500-4500	2.2	

41	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. *Blood*, **2019**, 134, 3037-3037	2.2	
40	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. *Blood*, **2019**, 134, 3300-3300	2.2	
39	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e76-e85	4.7	53
38	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. *American Journal of Hematology*, **2019**, 94, 338-345	7.1	11
37	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. *Blood*, **2019**, 133, 697-709	2.2	253
36	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. *Haematologica*, **2018**, 103, e237-e240	6.6	9
35	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. *British Journal of Haematology*, **2018**, 182, 141-145	4.5	2
34	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. *British Journal of Haematology*, **2018**, 183, 421-427	4.5	25
33	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. *Blood*, **2018**, 132, 1857-1857	2.2	
32	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. *Blood*, **2018**, 132, 586-586	2.2	1
31	Hemolytic Uremic Syndrome Associated With O157 Infection in an Allogenic Stem Cell Transplant Recipient. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2018**, 2, 387-391	3.1	1
30	Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside. *Clinical and Translational Science*, **2018**, 11, 537-539	4.9	2
29	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. *Cell*, **2018**, 173, 1439-1453.e19	56.2	197
28	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. *Blood*, **2017**, 129, 2395-2407	2.2	116
27	The Microbiome and Immune Regulation After Transplantation. *Transplantation*, **2017**, 101, 56-62	1.8	15
26	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. *Cancer Discovery*, **2017**, 7, 1154-1167	24.4	98
25	Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model. *Biology of Blood and Marrow Transplantation*, **2017**, 23, S19-S20	4.7	12
24	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. *American Journal of Hematology*, **2017**, 92, 1362-1369	7.1	8

23	Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. *Methods in Molecular Biology*, **2017**, 1633, 267-276	1.4	6
22	Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. *BioDrugs*, **2017**, 31, 473-481	7.9	80
21	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. *Leukemia and Lymphoma*, **2017**, 58, 1376-1383	1.9	30
20	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 235-246	4.7	58
19	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. *Clinical Cancer Research*, **2016**, 22, 2684-96	12.9	108
18	Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1000-1000	2.2	1
17	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. *Blood*, **2016**, 128, 652-652	2.2	24
16	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. *Blood*, **2016**, 128, 766-766	2.2	9
15	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. *Blood*, **2016**, 128, 5585-5585	2.2	
14	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. *Blood*, **2016**, 128, 300-300	2.2	
13	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. *Blood*, **2016**, 128, 3228-3228	2.2	
12	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *Journal of Clinical Investigation*, **2016**, 126, 3814-3826	15.9	352
11	273. Genome Editing Using CRISPR-Cas9 to Increase the Therapeutic Index of Antigen-Specific Immunotherapy in Acute Myeloid Leukemia. *Molecular Therapy*, **2016**, 24, S108	11.7	4
10	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, S19-S21	4.7	21
9	Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia. *Current Hematologic Malignancy Reports*, **2016**, 11, 253-64	4.4	15
8	Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. *Blood*, **2016**, 127, 1960-6	2.2	37
7	Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. *Modern Pathology*, **2015**, 28, 367-72	9.8	17
6	Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells **2015**, 3,		2

5	Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States: 1973 to 2010. *Chest*, **2015**, 147, e164-e165	5.3	8
4	CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2015**, 21, S25-S26	4.7	4
3	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. *Blood*, **2015**, 126, 2523-2523	2.2	5
2	Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity. *Blood*, **2015**, 126, 565-565	2.2	11
1	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. *Blood*, **2015**, 126, 852-852	2.2	10